(CercleFinance.com) – Merck today announced the results of a phase 3 trial (KEYNOTE-671) evaluating Keytruda as a perioperative treatment regimen, i.e. before surgery (neoadjuvant) and after surgery (adjuvant), for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC).
‘The results of this trial represent an important step in our fight to improve treatment outcomes for patients with surgically resectable non-small cell lung cancer. Adding perioperative Keytruda to standard chemotherapy followed by surgery reduced the risk of death by 28% compared to placebo,’ said Dr. Jonathan Spicer, associate professor of surgery at the McGill University Health Center. and trial researcher.
These late-breaking data are being presented for the first time today in a communications session at the 2023 European Society for Medical Oncology (ESMO) Congress.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
